Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu AH70212
- Development stage
- Phase 1
- Lead developer
- Lundbeck
- Modality
- Small Molecules
01
Overview
**Lu AH70212** is an investigational **small-molecule** drug candidate from **Lundbeck** being studied for **narcolepsy**. Publicly identifiable information is currently very limited: a first-in-human Phase 1 CTIS study initiated in 2026 is evaluating the safety and tolerability of Lu AH70212 together with Lu AH69593 in healthy adults, and the medical condition listed for the program is narcolepsy. No confirmed international nonproprietary name, brand name, dosage form, route, or validated target/mechanism has been clearly disclosed in the accessible primary sources reviewed, so its precise pharmacology should presently be treated as undisclosed.
Beyond the preview
Go deeper on Lu AH70212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lu AH70212.